Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Non Operating Income (2016 - 2023)

Historic Non Operating Income for UroGen Pharma (URGN) over the last 7 years, with Q4 2023 value amounting to -$715000.0.

  • UroGen Pharma's Non Operating Income fell 7964.82% to -$715000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was -$689000.0, marking a year-over-year decrease of 16197.72%. This contributed to the annual value of -$669000.0 for FY2024, which is 290.28% up from last year.
  • As of Q4 2023, UroGen Pharma's Non Operating Income stood at -$715000.0, which was down 7964.82% from $71000.0 recorded in Q3 2023.
  • Over the past 5 years, UroGen Pharma's Non Operating Income peaked at $989000.0 during Q1 2019, and registered a low of -$715000.0 during Q4 2023.
  • Over the past 4 years, UroGen Pharma's median Non Operating Income value was -$15000.0 (recorded in 2023), while the average stood at -$8923.1.
  • Data for UroGen Pharma's Non Operating Income shows a peak YoY increase of 33125.0% (in 2022) and a maximum YoY decrease of 41688.31% (in 2022) over the last 5 years.
  • Quarter analysis of 4 years shows UroGen Pharma's Non Operating Income stood at $989000.0 in 2019, then plummeted by 107.79% to -$77000.0 in 2021, then plummeted by 416.88% to -$398000.0 in 2022, then plummeted by 79.65% to -$715000.0 in 2023.
  • Its Non Operating Income was -$715000.0 in Q4 2023, compared to $71000.0 in Q3 2023 and -$30000.0 in Q2 2023.